Dana-Farber Cancer Institute: Clinical Trial Points to Treatment Advances for Glioma Patients for First Time in Decades
June 05, 2023
June 05, 2023
BOSTON, Massachusetts, June 5 (TNSres) -- The Dana-Farber Cancer Institute issued the following news release on June 4, 2023:
* * *
In the phase 3 INDIGO clinical trial co-led by Dana-Farber Cancer Institute, vorasidenib significantly prolonged progression free survival and delayed radiation and chemotherapy for patients with Grade 2 IDH-mutant glioma.
* * *
In a global phase 3, double-blinded, randomized clinical trial, a precision therapy cal . . .
* * *
In the phase 3 INDIGO clinical trial co-led by Dana-Farber Cancer Institute, vorasidenib significantly prolonged progression free survival and delayed radiation and chemotherapy for patients with Grade 2 IDH-mutant glioma.
* * *
In a global phase 3, double-blinded, randomized clinical trial, a precision therapy cal . . .